ÁøÇ༺ ³ëÀÎ À§¾Ï¿¡ ´ëÇÑ Ç׾Ͽä¹ý
Chemotherapy for Advanced Gastric Cancer in Elderly Patients
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 5È£ p.521 ~ p.529
±è¹ÌÁ¤(Kim Mi-Jung) - ±¹¸³¾Ï¼¾ÅÍ À§¾Ï¼¾ÅÍ
¹Ú¼÷·Ã(Park Sook-Ryun) - ¿ï»ê´ëÇб³ ÀÇ°ú´ëÇÐ ¼¿ï¾Æ»êº´¿ø ³»°ú
Abstract
Cancer, including gastric cancer, occurs predominantly in older patients. Although there is no single internationally accepted standard chemotherapy regimen for unresectable or metastatic gastric cancer (MGC), doublet combination chemotherapy using fluoropyrimidine and platinum is regarded as the reference treatment. However, most of the clinical trials that were based on the current treatment guidelines were performed in patients < 70 years of age with good performance status (PS). Therefore, the clinical application of these guidelines to elderly individuals is limited. The available data suggest that older patients with good PS are able to tolerate the same chemotherapy regimens as younger patients with MGC, and that they achieve a similar efficacy. In contrast, some studies showed that the same efficacy was achieved at the expense of increased toxicity in older patients, emphasizing the importance of patient selection. Many studies have actively investigated elderly patients with MGC, including randomized phase 3 studies comparing fluoropyrimidine and platinum doublets with fluoropyrimidine alone. Although an advanced age alone should not preclude the use of effective chemotherapy in MGC, more data regarding age-specific clinical trials are needed to guide optimal treatment in elderly patients.
Å°¿öµå
ÁøÇ༺ À§¾Ï, ³ëÀÎ, Ç×¾ÏÈÇпä¹ý
Advanced gastric cancer, Elderly, Chemotherapy
KMID :
0882420140870050521
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)